01873nas a2200325   4500000000100000008004100001260001200042653001100054653001900065653001100084653003100095653001800126653001300144653001200157653001700169653004000186653001300226100001300239700001100252700001500263700001400278700001500292700001100307245008200318856006000400300001400460490000700474520105200481022001401533       2023                            d  c07/202310aBrazil10aHansen disease10aMexico10aMycobacterium lepromatosis10aUnited States10aBacteria10aleprosy10aMycobacteria10aTuberculosis and other mycobacteria10aZoonoses1 aCollin S1 aLima A1 aHeringer S1 aSanders V1 aPessotti H1 aDeps P00aSystematic Review of Hansen Disease Attributed to Mycobacterium lepromatosis.  uhttps://wwwnc.cdc.gov/eid/article/29/7/pdfs/23-0024.pdf  a1376-13850 v293 a<p>In 2008, bacilli from 2 Hansen disease (leprosy) cases were identified as a new species, Mycobacterium lepromatosis. We conducted a systematic review of studies investigating M. lepromatosis as a cause of HD. Twenty-one case reports described 27 patients with PCR-confirmed M. lepromatosis infection (6 dual M. leprae/M. lepromatosis): 10 case-patients in the United States (7 originally from Mexico), 6 in Mexico, 3 in the Dominican Republic, 2 each in Singapore and Myanmar, and 1 each in Indonesia, Paraguay, Cuba, and Canada. Twelve specimen surveys reported 1,098 PCR-positive findings from 1,428 specimens, including M. lepromatosis in 44.9% (133/296) from Mexico, 3.8% (5/133) in Colombia, 12.5% (10/80) in Brazil, and 0.9% (2/224) from the Asia-Pacific region. Biases toward investigating M. lepromatosis as an agent in cases of diffuse lepromatous leprosy or from Mesoamerica precluded conclusions about clinicopathologic manifestations and geographic distribution. Current multidrug treatments seem effective for this infection.</p>
  a1080-6059